Download Curriculum Vitae - Bangalore INDIA NANO

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Research Accomplishments:
I participated in the development of the use of Surface Enhanced Raman Spectroscopy nanoparticles for
the detection of signaling events in single cancer cell. Raman Spectroscopy relies on inelastic scattering, or Raman
scattering. Spontaneous Raman scattering is typically very weak. However, the Composite Organic-Inorganic
Nanoparticles (COINs) used by us have enhanced Raman spectra. Each particle has a different Raman tag
generating a unique fingerprint Raman spectra. This approach has tremendous advantages over the commonly
used fluorescence tags. Fluorescence has broad overlapping spectra making the use of multiple tags
simultaneously difficult. On the other hand, COINs have narrow peak spectra and therefore are more useful for
multiple tag use theoretically we can do 100 such measurements. We had technical know how to use 9 COINs
simultaneously for cell signaling measurements in cancer cells. Intel, Santa Clara transferred technology to
Stanford for Immunoassay and biological applications. I used these COINs for studying signaling networks in live
and dead cells. We also used them for drug delivery into lung cancer cells.I Applied for patent at Stanford
University entitled “Determination of DNA copy number by Flow cytometry”.
I showed for the first time that the
oxidative stress leads to hepatocellular carcinoma in mouse models. Previously, only oncogenes over expression
models were employed to characterize liver tumors. I showed that knocking a gene from oxidative pathway (Copper
Zinc Superoxide dismutase) lead to hepatocellular carcinoma. This paper was well received and has 141 citations
till today. I later discovered biomarkers for tumor progression by employing proteomic approach. At Sankara
Netralaya graduate student Ms Kalmodia fabricated gold nanoparticles with SERS signature using green
nanotechnology under my supervision. We are applying for Patent)
Summary of qualification











Molecular Biologist working at the intersection of technology and traditional laboratory research in different
departments at Stanford University
Expertise in developing, implementing and managing multidisciplinary projects
Extensive experience with both cellular assays and DNA and protein techniques including gene expression,
2D gels and mass spectrometry, Northern and Southern blotting, Flow Cytometry, HPLC, antibody
detection, immunohistochemistry and conjugation to fluorophores and nanoparticles, RTPCR, cloning,
library screens, sequencing, electrophoresis, fluorescence, EPR and Raman spectroscopy.
Experience with mouse models for understanding tumor progression and neurodegeneration (Sod1-/-, Myc
overexpression under the control of TET promoter, Sod2-/-) human tissue, blood samples and tumor cell
lines.
Strong problem solving and organizational skills
Excellent oral and written communication skills
Fabrication of composite organic and inorganic nanoparticles.
Strong writing skills with 27 published papers in peer reviewed journals
Has funded grants as principal investigator and co-principal investigator.
Supervised grad students and post doctoral students.
Interacted with Stanford Nanotechnology Centre CCNE(centre for cancer Nanotechnology Therapy
Response) http://mips.stanford.edu/grants/ccne/ http://mips.stanford.edu/grants/ccne/postdocs.html
PROFESSIONAL
EXPERIENCE
Scientist Sankaranetralaya, Chennai-2011 (Accepted grants as Investigator).
 Fabrication of Mdm2 peptide conjugated Gold Nanoparticles for targeted
therapy of Retinoblastoma (Co-PI)
 Aptamer-Based Radiopharmaceuticals for Diagnostic Imaging and Targeted
Radiotherapy of Epithelial Cancers (Co-PI)
 Proteomics and Phosphoproteomics by Mass spectrometry and Flow cytometry
in Retinoblastoma. (Bioinformatic collaborator Dr Debashis Shaoo is from
Stanford University. Dr Akhilesh Pandey and Dr Harsha from Institute of
Bioinformatics) (PI)
 Centre for excellence and innovations in Biotechnology “Retinoblastoma
Research-Therapeutics” Team leader Dr Krishna Kumar. Co-Team leader along
with Dr Narayanan.
2005-2009 Research Scientist Department of Microbiology and Immunology, Baxters Labs
for Genetic Pharmacology, Stanford University Palo Alto CA
http://www.stanford.edu/group/nolan/members/members.html Collaborated with Intel Corporation
having 20 member team on it for developing cell assay for biomarker discovery using nanoparticles and Raman Spectroscopy in comparison with Flow Cytometry data. Developed
methodology for live cell signaling in Lung cancer cell lines using nanoparticles Performed
nanoparticle drug delivery for curing tumors in mouse models. Developed new flow cytometry
techniques for single cell determination of gene expression and gene copy number using FACS.
Contributed to identifying threshold of MYC expression using TET system leading to disease
formation in lymphoma cells and lymphoma tissues using proteomics (2D gels and mass
spectrometry), DNA arrays, quantitative PCR, Western blotting. Employed mouse models of
lung, human tumor samples and lung cancer cell lines to detect alteration in pathways and
signaling under disease conditions using proteomics, spectrometry, quantitative PCR and Flow
Cytometry. Provided rigorous trouble shooting and fine tuning of the assay to produce the best
method for sensitive and reproducible detection.
2000-2004Postdoctoral Fellow. Dept. of Neurology & Neuroscience - Stanford University,
Palo Alto CA (2002 – 2004) Dept. of Pediatrics – San Francisco University San Francisco,
CA (2000 – 2002)
Successfully identified of pathways leading to hepatocarcinogenesis and neurodegeneration in
CuZn superoxide dismutase (SOD) and MnSOD, CuZnSOD knockout mice using proteomics,
quantitative PCR, western blots and immuno-histochemistry. Identified cancer biomarkers
associated with tumor progression. Identified the genetic modifiers affecting the lifespan of Sod2/- mice using 250 whole genomic mouse MIT markers to do quantitative loci determination by 6
generations of back cross. Showed in Ts65 mice, partial extra chromosome16 not only caused
Down syndrome but also increased oxidative stress. Using biochemical assays and QPCR
identified that low density grown neural stem cells had oxidative stress compared to high density
grown cells.
PUBLICATIONS:
1. Kode K, Shachaf CM, Elchuri SV, Garry Nolan, David S. Paik Raman Labeled Nanoparticles for In-vivo
Imaging: Characterization of Variability and Improved Method for Unmixing (J of Raman Spectroscopy)
(2012) (accepted).
2. Subramaniyan N, Raghunathan V , Kanwar JR, Kanwar RK, Elchuri SV, Khetan V, Subramanian K.
Target specific delivery of Doxorubicin to Retinoblastoma using EpCAM Aptamer (2012) Molecular Vision
2012;18:2783-95
3. Shachaf CM, Elchuri SV, Koh AL, Zhu J, Nguyen LN, Mitchell DJ, Zhang J, Swartz KB, Sun L, Chan S,
Sinclair R, Nolan GP. A novel method for detection of phosphorylation in single cells by surface enhanced
Raman scattering (SERS) using composite organic-inorganic nanoparticles (COINs). PLoS One.
b2009;4(4):e5206. Times Cited: 5 . This work is high lighted in Bioanalysis Journal Title: Nanoparticle
'fingerprinting' technique could improve cancer diagnosis Author(s): [Anon]Source: BIOANALYSIS Volume: 1
Issue: 2 Pages: 270-270 Published: MAY 2009
4. Koh AL, Shachaf CM, Elchuri S, Nolan GP, Sinclair R. Electron microscopy localization and
characterization of functionalized composite organic-inorganic SERS nanoparticles on leukemia cells.
Ultramicroscopy. 2008 Dec;109(1):111-21. Times Cited: 8
5. Shachaf CM, Gentles AJ, Elchuri S, Sahoo D, Soen Y, Sharpe O, Perez OD, Chang M, Mitchel D,
Robinson WH, Dill D, Nolan GP, Plevritis SK, Felsher DW. Genomic and proteomic analysis reveals a
threshold level of MYC required for tumor maintenance. Cancer Res. 2008 Jul 1;68(13):5132-42. (Second
author). Times Cited: 21 (Article selected by Faculty as 1000 best papers of the year)
6. Shachaf CM, Perez OD, Youssef S, Fan AC, Elchuri S, Goldstein MJ, Shirer AE, Sharpe O, Chen J,
Mitchell DJ, Chang M, Nolan GP, Steinman L, Felsher DW. Inhibition of HMGcoA reductase by atorvastatin
prevents and reverses MYC-induced lymphomagenesis. Blood. 2007 Oct 1;110(7):2674-84. Times Cited: 18
7. Elchuri S, Naeemuddin M, Sharpe O, Robinson WH, Huang TT. Identification of biomarkers associated
with the development of hepatocellular carcinoma in CuZn superoxide dismutase deficient mice.
Proteomics. 2007 Jun;7(12):2121-9. Times Cited: 10
8. Erker L, Schubert R, Elchuri S, Huang TT, Tarin D, Mueller K, Zielen S, Epstein CJ, Wynshaw-Boris A.
Effect of the reduction of superoxide dismutase 1 and 2 or treatment with alpha-tocopherol on
tumorigenesis in Atm-deficient mice. Free Radic Biol Med. 2006 Aug 15;41(4):590-600. Times Cited: 10
9. Huang TT, Naeemuddin M, Elchuri S, Yamaguchi M, Kozy HM, Carlson EJ, Epstein CJ. Genetic modifiers
of the phenotype of mice deficient in mitochondrialsuperoxide dismutase. Hum Mol Genet. 2006 Apr
1;15(7):1187-94. Epub 2006 Feb 23. Times Cited: 32
10. Lynn S, Huang EJ, Elchuri S, Naeemuddin M, Nishinaka Y, Yodoi J, Ferriero DM, Epstein CJ, Huang TT.
Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice.
Free Radic Biol Med. 2005 Mar15;38(6):817-28. Times Cited: 14
11. Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, Huang TT.
CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later
in life. Oncogene. 2005 Jan13;24(3):367-80. Times Cited: 141
12. Limoli CL, Rola R, Giedzinski E, Mantha S, Huang TT, Fike JR. Cell-density-dependent regulation of
neural precursor cell function. Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):16052-7. Times sited 57
13. Huang TT., Mantha S., Epstein C.J. (2004) The role of oxidative damage in the pathogenesis of Down
syndrome. In Redox-Genome Interactions in Health and Disease, Eds, J. Fuchs, M. Podda, L. Packer as
the Oxidative Stress and Disease series (Eds L. Packer and E. Cadenas). Marcel Dekker, Inc. New York,
Basel. pp 409-424
14. Huang TT, Carlson EJ, Kozy HM, Mantha S, Goodman SI, Ursell PC, Epstein CJ.Genetic modification of
prenatal lethality and dilated cardiomyopathy in Mn superoxide dismutase mutant mice. Free Radic Biol
Med. 2001 Nov 1;31(9):1101-10. Times Cited: 45
ABSRTACTS
1. Kode K, Shachaf C, Elchuri S, Nolan G, Paik DS. "Parametric Modeling of Raman Spectra of Nanoparticles for
Quantitative Unmixing." accepted to World Molecular Imaging Congress (WMIC), Montreal, Canada, September
2009. http://www.wmicmeeting.org/abstracts/data/papers/0705.html
2. Kode K, Elchuri S, Shachaf C, Paik D. "Parametric Modeling of Raman Spectra of Nanoparticles for
Quantitative Unmixing.", 9th Symposium, Biomedical Computation at Stanford, October 2008.
3. Shachaf CM, Elchuri S, Zhu J, Nguyen, Zhang J, Sun L, Chang S, and Nolan GP. Detection of surface
molecules and phosphorylation events by surface enhanced raman scattering (SERS) using composite organicinorganic nanoparticles (COINs) in single cells. AACR Meeting Abstracts, Apr 2008; 2008: 4742.
4. Shachaf C, Gentles A, Elchuri S, Sahoo D, Chang M, Sharpe O, Nolan GP, Plevritis S, and Felsher D. Genomic
and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. AACR Meeting
Abstracts, Apr 2008; 2008: 91
AiLeen K, Shachaf CM, Elchuri S, Nolan GP, Sinclair R Electron microscopy characterization of composite
organic inorganic nanoparticles (COINs) for extra cellular analyses. Microscopy and Microanalyses meeting
2008
5. Shachaf CM, Perez OD, Youssef S, Chang M, Elchuri S, Goldstein MJ, Nolan GP, Steinman L and Felsher
DW. American Society of Cell Biology. 2005 Annual meeting.
6. Shachaf C, Perez O, Elchuri S, Mitchell D, Felsher D, and Nolan GP. Targeting HMGcoA reductase for
prevention of MYC expressing lymphoma. AACR Meeting Abstracts, Oct 2007; 2007: C181.
7. Clement, MH,Chandra S, Mantha S, Huang TT, Valentine JS, Gralla EB “ EPR iron homeostasis studies in
organisms lacking Cu/Zn superoxide dismutase” retreat in Chemistry biology interface organized by Chemistry
and Biochemistry Department of University of California at Los Angels (2003).
8. Elchuri S, Oberley TD, Van Remmen H, Epstein, CJ, and Huang TT, “Increased oxidative stress leads to the
development of hepatocellular carcinoma in CuZnSOD mutant mice,” 43rd Annual Meeting, American Society
for Cell Biology, San Francisco, CA, 2003.
9. Mantha SV, Oberley, TD, Van Remmen H, Epstein, CJ and Huang T-T, “Increased oxidative stress and
dysregulation of cell cycle proteins in CuZnSOD deficient mice,” selected for oral presentation, 9th annual
meeting, The Oxygen Society, San Antonio, TX, Nov 2002.
10. Mantha S, Oberley TD, Epstein CJ, Huang T-T, “Hepatocellular carcinoma and altered aconitase activities in
CuZn superoxide dismutase deficient mice,” Free Radical Biology and Medicine 31: 288, Suppl, 2001.
12 published papers in Plant Sciences will be provided on request.
Accepted
15) Sushma Kalmodia , Jaidev Rajeswari.R , Wenrong Yang , Colin J. Barrow2S. Ramaprabhu,
Subramanian Krishnakumar , Sailaja Elchuri. Synthesis of SERS active Gold Nano particles. International
Journal of Nanomedicine (accepted)
16) Targeted Expression of Suicide Gene by Tissue-specific Promoter and microRNA Regulation for
Cancer Gene Therapy. Ravikanth Danda, Gopinath Krishnan , Khetan V, Sailaja Elchuri Nivedita
Chatterjee, Krishnakumar S. (PLOS one accepted)
Under Submission:



Elchuri VS, KimS, Zare R, Nolan GP Shachaf CM: DNA copy number detection by Flow cytometry. (Nature
Methods)
Elchuri SV, Shachaf CM, Tabackman S, Dai H, Nolan GP. Dynamic cellular signaling in lung cancer using
COIN nanoparticles. (Nano Letters)
Elchuri SV, Shachaf CM, Nolan GP. Novel biomarkers in lung cancer signaling using COIN nanoparticles.
ACS Nano)
Web releases:
 New imaging tool could improve cancer diagnosis
 Nanoparticles use Raman tags to highlight features within cells
Collaborations:
Ongoing Research Projects
Sl No.
Title of Project
Funding Agency
Amount
Fabrication
of
Mdm2 DST No SR/NM/NSpeptide conjugated Gold 83/2010
Nanoparticles for targeted
therapy of Retinoblastoma
45,35,200
No. 2010/
Aptamer-Based
35/19/BRNS
Radiopharmaceuticals
for
Diagnostic Imaging and
Targeted Radiotherapy of
Epithelial Cancers
45,00,000
Proteomics
and
Phospho- BT/01/CEIB/11/V/16
proteomics
by
Mass
spectrometry
in
Retinoblastoma
1,20,00,000
Engineer a aptamer-siRNA
chimeric conjugates for
targeting epithelial
cancers"
Date of sanction
and Duration
22nd july 20112014
July, 2011 for 3
years
2012 for 4yrs
3yrs
Funds released
30 lakhs for one
year
(consumables
and equipment
payment for 2
SRFS